Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985 Jul;20(1):67–76. doi: 10.1111/j.1365-2125.1985.tb02800.x

Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

G C Kahn, A R Boobis, M J Brodie, E L Toverud, S Murray, D S Davies
PMCID: PMC1400628  PMID: 4027138

Abstract

Phenacetin O-deethylase activity was impaired, both in vivo and in vitro, in poor metabolisers of debrisoquine, consistent with the work of others. No impairment was observed in the oxidation of acetanilide, amylobarbitone or antipyrine in the PM phenotype. There was a good correlation (r = 0.804) between the high affinity component of phenacetin O-deethylase and debrisoquine 4-hydroxylase activities. No such correlation was observed with the low affinity component of phenacetin O-deethylase activity. Although debrisoquine was a competitive inhibitor of phenacetin O-deethylase activity, phenacetin was without effect on debrisoquine 4-hydroxylation. There was also marked differences in the effects of sparteine, guanoxan and alpha-naphthoflavone on the two activities. Cigarette smoking was associated with a significant, two-fold, increase in phenacetin O-deethylase activity whilst debrisoquine 4-hydroxylase activity was not affected. It is concluded that the high affinity component of phenacetin O-deethylase and debrisoquine 4-hydroxylase activities are catalysed by different isozymes of cytochrome P-450 but that these are most probably regulated by closely linked genes.

Full text

PDF
72

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boobis A. R., Brodie M. J., Kahn G. C., Fletcher D. R., Saunders J. H., Davies D. S. Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens. Br J Clin Pharmacol. 1980 Jan;9(1):11–19. doi: 10.1111/j.1365-2125.1980.tb04790.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Boobis A. R., Brodie M. J., Kahn G. C., Toverud E. L., Blair I. A., Murray S., Davies D. S. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol. 1981 Dec;12(6):771–777. doi: 10.1111/j.1365-2125.1981.tb01305.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boobis A. R., Davies D. S. Human cytochromes P-450. Xenobiotica. 1984 Jan-Feb;14(1-2):151–185. doi: 10.3109/00498258409151404. [DOI] [PubMed] [Google Scholar]
  4. Boobis A. R., Murray S., Hampden C. E., Davies D. S. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol. 1985 Jan 1;34(1):65–71. doi: 10.1016/0006-2952(85)90101-7. [DOI] [PubMed] [Google Scholar]
  5. Boobis A. R., Murray S., Kahn G. C., Robertz G. M., Davies D. S. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol. 1983 Mar;23(2):474–481. [PubMed] [Google Scholar]
  6. Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 1981 Jan;11(1):89–91. doi: 10.1111/j.1365-2125.1981.tb01108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Eichelbaum M. Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982 Jan-Feb;7(1):1–22. doi: 10.2165/00003088-198207010-00001. [DOI] [PubMed] [Google Scholar]
  8. Grove J., Toseland P. A. The excretion of hydroxyamylobarbitone in man after oral administration of amylobarbitone and hydroxyamylobarbitone. J Pharm Pharmacol. 1971 Dec;23(12):936–940. doi: 10.1111/j.2042-7158.1971.tb09896.x. [DOI] [PubMed] [Google Scholar]
  9. Kahn G. C., Boobis A. R., Murray S., Brodie M. J., Davies D. S. Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol. 1982 May;13(5):637–645. doi: 10.1111/j.1365-2125.1982.tb01430.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kellermann G., Luyten-Kellermann M. Benzo(a)pyrene metabolism and plasma elimination rates of phenacetin, acetanilide and theophylline in man. Pharmacology. 1978;17(4):191–200. doi: 10.1159/000136854. [DOI] [PubMed] [Google Scholar]
  11. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  12. Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984 Jan 2;34(1):73–80. doi: 10.1016/0024-3205(84)90332-1. [DOI] [PubMed] [Google Scholar]
  13. Otton S. V., Inaba T., Kalow W. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci. 1983 Feb 14;32(7):795–800. doi: 10.1016/0024-3205(83)90315-6. [DOI] [PubMed] [Google Scholar]
  14. Otton S. V., Inaba T., Mahon W. A., Kalow W. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Can J Physiol Pharmacol. 1982 Jan;60(1):102–105. doi: 10.1139/y82-017. [DOI] [PubMed] [Google Scholar]
  15. Shahidi N. T. Acetophenetidin-induced methemoglobinemia. Ann N Y Acad Sci. 1968 Jul 31;151(2):822–832. doi: 10.1111/j.1749-6632.1968.tb48266.x. [DOI] [PubMed] [Google Scholar]
  16. Sloan T. P., Mahgoub A., Lancaster R., Idle J. R., Smith R. L. Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J. 1978 Sep 2;2(6138):655–657. doi: 10.1136/bmj.2.6138.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Spina E., Birgersson C., von Bahr C., Ericsson O., Mellström B., Steiner E., Sjöqvist F. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther. 1984 Nov;36(5):677–682. doi: 10.1038/clpt.1984.239. [DOI] [PubMed] [Google Scholar]
  18. Toverud E. L., Boobis A. R., Brodie M. J., Murray S., Bennett P. N., Whitmarsh V., Davies D. S. Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 1981;21(2):155–160. doi: 10.1007/BF00637517. [DOI] [PubMed] [Google Scholar]
  19. Wiebel F. J., Gelboin H. V. Aryl hydrocarbon (benzo[a]pyrene) hydroxylases in liver from rats of different age, sex and nutritional status. Distinction of two types by 7,8-benzoflavone. Biochem Pharmacol. 1975 Aug 15;24(16):1511–1515. doi: 10.1016/0006-2952(75)90028-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES